Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
But now it must show that varseta-M can move into a registrational trial.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
New data with pasritamig plus docetaxel support a recent pivotal start.
